Even for topical use, certain groups have a higher risk profile or simply lack the data to make an informed judgment
What are the geographies covered for clinical trials in GLP-1 agonists
In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment, said Anna Gloyn, DPhil, professor of pediatrics and of genetics, and one of the studys senior authors
and (ii) control arm ( n = 18) all patients received glimepiride (GLIME) in a daily dose of 2 mg, which could be titrated up to 4 mg if the glycaemic control was not satisfactory [105]
At the same time, researchers note that most Americans already consume plenty of protein, averaging about 1 gram per kilogram of body weight